Pinsent Masons advises GNA Biosolutions GmbH on Covid-19 rapid PCR test

11 Jan 2021 | 10:23 am | 1 min. read

Multinational law firm Pinsent Masons advised GNA Biosolutions GmbH on IP and commercial aspects of its rapid PCR Covid-19 test.

The test, developed by German molecular diagnostics company GNA Biosolutions, has been approved by the domestic regulatory German Federal Institute for Drugs and Medical Devices (BfArM). The new PCR test, which produces a result in 40 minutes, is being rolled out across Germany with EU-wide approval expected in the coming months

The reliability of the rapid test system by GNA Biosolutions is comparable to common PCR tests, which, however, require up to 48 hours for a result.

The Pinsent Masons team advising on the deal was led by corporate partner Tobias Rodehau and included head of German public and regulatory Dr. Anke Empting, commercial and IP partner Dr. Michael Reich, technology, science and industry sector head Dr. Florian von Baum, head of German IP Marc Holtorf, and commercial legal director Dr. Igor Barabash.

Commenting on the project, Tobias Rodehau, said: "We are proud to have been able to assist GNA Biosolutions GmbH with this important project. Thanks to our expertise in the life sciences sector, we are familiar with the specifics of this industry and have been able to assemble a cross disciplinary team to play a role in facilitating swift access to this groundbreaking technology."

GNA Biosolutions GmbH is a long-standing client of Pinsent Masons. In 2019 the firm successfully advised the company on its USD 13.5 million Series C financing.

The Bavarian state government has acquired six GNA Biosolutions test devices, which were officially approved in December, as well as 60,000 test kits.

Meet the team

Show me all
Tobias Rodehau

Rechtsanwalt, Partner

Tobias specialises in small and mid-cap private equity transactions, with a focus on venture capital transactions.

Tobias Rodehau
Dr. Florian von Baum

Rechtsanwalt, Partner, Sector Head Technology, Science & Industry

Florian is the Global Head of Technology, Science & Industry

von Baum Florian
Marc L. Holtorf

Rechtsanwalt, Partner, Head of German Life Sciences

Marc is Deputy Head of Pinsent Masons Germany. He also heads the German Life Sciences team. He specialises in supporting pharmaceutical, medical device and other high-tech companies in navigating through the complex world of contentious and non-contentious intellectual property.

Marc Holtorf

Key Contacts

Latest press releases

Show me all press releases

Pinsent Masons promotes 24 to global partnership

Multinational law firm Pinsent Masons has today announced its latest round of partner promotions, with 24 set to join its global partnership on 1 May.

Pinsent Masons advises Azets Ireland on acquisition of Cooney Carey

Multinational law firm Pinsent Masons has advised Azets Ireland on the merger with Cooney Carey, combining two of Ireland’s leading accountancy, tax and business advisory firms.

Pinsent Masons appoints first employment practice head in Riyadh

Multinational law firm Pinsent Masons has today announced the hire of Dr. Sairah Narmah-Alqasim to head up the employment practice for its newly launched Riyadh office in the Kingdom of Saudi Arabia (KSA).

People who viewed this press release also viewed

Show me all press releases

Pinsent Masons advises Elphinstone Group on takeover bid

Multinational law firm Pinsent Masons has advised Australian heavy machinery manufacturer Elphinstone Group on its proposed takeover bid for Engenco Limited, a provider of sustainable transportation products.

Pinsent Masons advises Fintech Asia Limited on reverse takeover

Multinational law firm Pinsent Masons has advised Fintech Asia Limited, a publicly listed company on the mainboard of the London Stock Exchange, in a reverse takeover of ICFG Pte. Ltd.

Pinsent Masons advises RRD on the acquisition of Williams Lea

Multinational law firm Pinsent Masons has advised R.R. Donnelley & Sons Company (RRD) on its acquisition of business support services provider Williams Lea from private equity investor, Advent.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts

We are processing your request. \n Thank you for your patience. An error occurred. This could be due to inactivity on the page - please try again.